Kubasch, A. S., Giagounidis, A., Metzgeroth, G., Jonasova, A., Herbst, R., Diaz, J. M. T., . . . Adès, L. (2022). Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms: Results of the EUROPE trial by EMSCO : myelodysplastic neoplasms. Leukemia, 36(10), . https://doi.org/10.1038/s41375-022-01669-z
Chicago-Zitierstil (17. Ausg.)Kubasch, Anne Sophie, et al. "Prospective Validation of a Biomarker-driven Response Prediction Model to Romiplostim in Lower-risk Myelodysplastic Neoplasms: Results of the EUROPE Trial by EMSCO : Myelodysplastic Neoplasms." Leukemia 36, no. 10 (2022). https://doi.org/10.1038/s41375-022-01669-z.
MLA-Zitierstil (9. Ausg.)Kubasch, Anne Sophie, et al. "Prospective Validation of a Biomarker-driven Response Prediction Model to Romiplostim in Lower-risk Myelodysplastic Neoplasms: Results of the EUROPE Trial by EMSCO : Myelodysplastic Neoplasms." Leukemia, vol. 36, no. 10, 2022, https://doi.org/10.1038/s41375-022-01669-z.